FacebookTwitterLinkedInEmailPrint分享Smart Energy International:Enel Green Power set a new record in 2019 within the renewable energy industry by building more than 3GW of capacity.Enel built around 190MW more renewable energy capacity in 2019 than in 2018, a 6.5% increase. The milestone makes Enel the largest private renewable energy player at global level Enel built 47 facilities of which the majority were wind (1,813 MW) and then solar (1,193 MW).Around 1,072MW was built in Europe, mainly in Spain, 997MW in Latin America, mainly in Mexico, 867MW in North America, mainly in the US and around 94MW in Africa, Asia and Oceania, mainly in South Africa.Renewable energy built by Enel in 2019 will generate 9.3TWh and avoid 5.85 million tons of carbon emissions per annum.The 2019 milestone increases Enel’s total renewable energy capacity to 46GW.The utility has set a goal of generating around 57% of its production from renewable sources in 2022. By adding 14.1 GW of renewable capacity to Enel will reach around 60GW renewable generation by 2022. The utility plans on being fully decarbonised by 2050.[Nicholas Nhede]More: Enel reached a new renewable energy milestone in 2019 Record year pushes total Enel Green Power renewable capacity to 46GW
Stat: Prominent ‘Right-To-Try’ Advocate Is Getting Treatment Under The New Law Columbus Dispatch: Trump’s Move On Drug Rebates Good But May Not Lower Prices, Experts Say A bipartisan group of senators is asking industry groups for information as they plan legislation to prevent patients from getting massive, unexpected medical bills. The lawmakers sent letters on Tuesday to a variety of insurers and medical providers asking detailed questions about data on their billing and payment procedures. (Sullivan, 2/5) In other pharmaceutical news — The Trump administration has made lowering drug prices one of its top priorities, and last week it unveiled a proposal that could vastly rewrite the way drugs are sold in the United States. The proposal takes aim at the secret deals that drug companies strike with pharmacy benefit managers, the industry intermediaries that negotiate the price of drugs for insurers and large employers. These after-the-fact discounts, called rebates, have come under harsh criticism and are blamed for helping to push up the list price of drugs, which consumers are increasingly responsible for paying. (Thomas and Abelson, 2/5) Bottom Line On Trump’s Plan To Target Rebates: Most People’s Costs Will Go Up Slightly, But Patients On Pricey Drugs Will Get Relief The New York Times takes a look at who will benefit from President Donald Trump’s new proposal to go after the complicated drug rebate system that flourishes between drugmakers and pharmacy benefit managers. One of the namesakes of the federal “right-to-try” law confirmed Tuesday that he gained access to an experimental treatment thanks to the new law. Matt Bellina, who has ALS, thanked the drug company BrainStorm for providing the treatment on Facebook. “Many of you read last June that Brainstorm would be treating me with the experimental treatment of [NurOwn] under the new federal Right to Try law. Today I want to thank the company and CEO Chaim Lebovitz for following through and keeping their word.” (Florko, 2/5) The New York Times: Making New Drugs With A Dose Of Artificial Intelligence The proposed rule would no longer shield the middlemen, known as pharmacy benefit managers, from federal anti-kickback laws if they keep part of the rebates they obtain from drugmakers. The three biggest middlemen — CVS Caremark, OptumRx and ExpressScripts — control more than 70 percent of the market, and they push makers of brand-name drugs to provide rebates in exchange for special access to their customers. (Candisky and Schladen, 2/5) You can think of it as a World Cup of biochemical research. Every two years, hundreds of scientists enter a global competition. Tackling a biological puzzle they call “the protein folding problem,” they try to predict the three-dimensional shape of proteins in the human body. No one knows how to solve the problem. Even the winners only chip away at it. But a solution could streamline the way scientists create new medicines and fight disease. (Metz, 2/5) The New York Times: How Trump’s Latest Plan To Cut Drug Prices Will Affect You This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription. The Hill: Bipartisan Senators Ask Industry For Information On Surprise Medical Bills Prescription Drug Watch: For more news on rising drug costs, check out our weekly roundup of news coverage and perspectives of the issue.